Symmetry Partners 13F: New $1.3M Stake in DexCom (DXCM)
Key Points
- Symmetry Partners opened a new position in DexCom, acquiring 15,400 shares valued at about $1.33 million.
- DexCom shares recently traded around $78.56, which is about equal to the event-day closing price of $78.56 on October 27, 2026.
- The company has a market cap of roughly $29.65 billion and is heavily involved in developing continuous glucose monitoring systems for diabetes management.
Get DexCom text alerts
We text you when insiders, Congress, analysts or big funds move on $DXCM.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated DexCom, Inc. alert may contain errors. Disclosures
Symmetry Partners has taken a new position in DexCom, Inc. (DXCM), acquiring 15,400 shares valued at approximately $1.33 million. This was disclosed in a filing on October 27, 2026.
DXCM
DexCom, Inc.
What Changed in Symmetry Partners' DexCom Position
Symmetry Partners opened a new position in DexCom, adding 15,400 shares to its holdings. This new stake represents 0.26% of the fund's reported value of about $515.5 million and ranks 25th among the fund's holdings.
Where DexCom Fits in Symmetry Partners' Portfolio
This new position is a notable addition given that it adds a significant dollar value to Symmetry Partners' portfolio, which consists of 358 reported positions.
Other Institutional Activity in DexCom
Several other institutional investors have also adjusted their stakes in DexCom recently. Baillie Gifford & Co reduced its holdings by 798,737 shares, now holding 14,801,590 shares valued at about $1.16 billion. Meanwhile, AllianceBernstein L.P. decreased its position by 1,230,341 shares, bringing its total to 11,693,409 shares worth approximately $918.6 million.
DexCom, Inc. Stock Holds Steady
DexCom shares closed at $78.56 on October 27, 2026, which is about equal to its recent trading price. The stock is currently below its 50-day moving average by about 9.1% but above its 200-day moving average by 5.6%. The stock is also 15.2% below its 52-week high of $92.59, yet 45.2% above its 52-week low of $54.11.
Recent Earnings
For the trailing twelve months, DexCom reported revenue of approximately $4.97 billion and an earnings per share (EPS) of $2.52. The next earnings report is scheduled for October 29, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
4 target cuts vs 0 raises.
-
EPS & revenue
EPS beat estimates by 17.0%. Revenue missed estimates by 0.5%.
-
Profit surprise
EBITDA beat by 5 percent. Operating income beat by 21 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
4 target cuts.
-
Earnings quality
Gross margin up 6.1 points. Operating margin up 8.5 points. Positive free cash flow.
Earnings Call Summary
DexCom delivered first-quarter revenue of $1.19 billion, up fifteen percent year over year, with strong international growth of twenty-six percent. The company achieved record global new patient starts and grew U.S. market share significantly in the type 2 non-insulin segment, driven by the G7 15-day launch and better product algorithms. Management highlighted upcoming announcements including randomized control trial results at the ADA conference and new basal insulin features designed to simplify diabetes treatment.
Guidance DexCom reaffirmed full-year revenue guidance of about $5.18 billion, representing growth of eleven to thirteen percent. The company raised full-year operating profit and EBITDA margin guidance, citing strong cost control and manufacturing improvements. Management expects continued momentum from the G7 15-day product launch and potential coverage expansion for type 2 non-insulin patients later in the year.
Clearly negative report. The company missed important expectations and likely triggers downward revisions.
Insider Buying and Selling at DexCom, Inc.
Recent insider activity includes several sales by company executives. On September 15, 2026, Officer Michael Jon Brown sold 1,700 shares for about $142,868. Director Nicholas Augustinos also sold 8,089 shares on the same day, valued at approximately $679,769. On September 28, 2026, Officer Sadie Stern sold 2,565 shares for about $220,975.
Analysts Set New Price Targets
Analysts have maintained a generally positive outlook on DexCom. On September 18, 2026, Truist Securities maintained a Buy rating with a price target of $102, while TD Cowen reiterated a Buy rating with a target of $95. RBC Capital maintained an Outperform rating with a target of $105, and Barclays initiated coverage with an Overweight rating and a target of $115.
About DexCom
DexCom, Inc. is a medical device company that specializes in continuous glucose monitoring (CGM) systems. These systems help manage diabetes and metabolic health both in the U.S. and internationally. The company's focus on innovative technology is crucial as it continues to expand its market presence.
Bottom Line
Investors should watch for DexCom's upcoming earnings report on October 29, 2026, to gauge its financial performance. Symmetry Partners' new position in DexCom highlights a growing interest in the healthcare sector, particularly in diabetes management solutions.
Related Filing Alerts
Source: Symmetry Partners's 13F filing on $DXCM (Oct 27, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts